The present invention relates to a sulfonylurea compound for use in thetreatment and/or amelioration of a disease that isassociated with UV-induced DNA damage, wherein the subject to be treatedexpresses enzymatically active mutY homolog (MUTYH),wherein the sufonylurea compound preferably is acetohexamide or a derivativethereof, or glimepiride or a derivative thereof. Theinvention furthermore relates to pharmaceutical compositions comprising asulfonylurea compound for use in the treatment and/oramelioration of a disease that is associated with UV-induced DNA damage. Also,a screening method for identifying a compound thattreats and/or ameliorates a disease that is associated with UV-induced DNAdamage in a subject that expresses enzymatically activeMUTYH is provided. The invention also relates to a method for monitoring thetherapeutic success during the treatment of a diseasethat is associated with UV-induced DNA damage in a subject and a method foridentifying a subject which responds to a treatmentwith a sulfonylurea compound.
